PricewaterhouseCoopers (PwC) expects more megadeals - transactions of at least $5 billion in value - in 2021, from pharma companies acquiring early-phase or pre-commercial products in hot therapeutic areas to bank consolidation as low-interest rates persist, plus private equity (PE) acquisitions.

"The M&A recovery that began in the second half of 2020 will